[News] Pfizer's Covid-19 Booster Dose Shows 95.6% Efficacy in Phase 3 Trial, Company Says

[Akrapovic]

This is how covid vaccines would be combined with booster doses

 

 

(CNN) - A booster dose of Pfizer / BioNTech's covid-19 vaccine is highly effective (95.6%) in a phase 3 trial, the companies announced Thursday. They noted that "efficacy was consistent regardless of age, sex, race, ethnicity, or comorbid conditions."

The trial included more than 10,000 fully vaccinated people, ages 16 and older, who were randomly given either the 30-microgram booster dose of the vaccine or a placebo. The average time between completing their second initial dose of vaccine and receiving a booster or placebo was about 11 months, the companies said.

Pfizer and BioNTech reported that, during the study, there were 109 cases of Covid-19 among people who received a placebo and five cases among those who received the third dose of the vaccine. The companies noted that the efficacy of the vaccine they found, of 95.6%, reflects that reduction in disease among those who received a booster shot versus those who did not.

Latin America is playing it by booster dose with messenger RNA. It is safe?
These are the first results of a randomized, controlled booster trial of the COVID-19 vaccine, the companies said, and reflect a period in which the highly contagious delta variant was prevalent.

"These results provide further evidence of the benefits of boosters, as our goal is to keep people well protected against this disease," said Albert Bourla, Pfizer president and CEO, in a press release Thursday.

"In addition to our efforts to increase access and global acceptance among the unvaccinated, we believe that booster doses have a critical role to play in addressing the current public health threat from this pandemic," Bourla said. "We look forward to sharing this data with health authorities and working together to determine how it can be used to support the launch of booster doses around the world."

USA: Recommend booster doses of J&J 3:21 vaccine
Booster dose and combination
In September, the U.S. Food and Drug Administration authorized a booster dose of the Pfizer / BioNtech coronavirus vaccine for emergency use in adults 65 years of age and older, adults at high risk for severe COVID-19. and adults with frequent exposure to coronavirus through their work.

Then this Wednesday, the FDA authorized the Pfizer / BioNTech booster for those who may be eligible but are fully vaccinated with the Moderna or Johnson & Johnson covid-19 vaccines, as a combination approach.

Today, vaccine advisers from the U.S. Centers for Disease Control and Prevention, the Advisory Committee on Immunization Practices, are meeting to decide whether to recommend the recent FDA combination clearance, as well as the clearance Modern and J&J reinforcements, and then the CDC director will decide whether to approve the ACIP guidance.

 

LINK: https://cnnespanol.cnn.com/2021/10/21/dosis-refuerzo-vacuna-covid-pfizer-eficacia-trax/